Cambridge Isotope Laboratories, Inc.

Cambridge Isotope Laboratories, Inc., doing business as Cambridge Isotope Labs, manufactures stable isotopes and isotope-labeled compounds for federal biomedical research as a foreign-owned, for-profit prime contractor across 349 of its 351 federal awards. The company is headquartered in Andover, Massachusetts, operates under primary NAICS 311911 (All Other Basic Organic Chemical Manufacturing), and competes exclusively in full-and-open procurements — no set-asides appear across the prime footprint.

Cambridge Isotope Labs holds a $10 million single-award blanket purchase agreement with the NIH Office of Logistics and Acquisition Operations running through January 31, 2027, which anchors the bulk of its federal revenue. Work under the BPA spans task orders from multiple NIH institutes — the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Aging (NIA), the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Heart, Lung, and Blood Institute (NHLBI) — for delivery of deuterium oxide (D2O), deuterated glucose (D-glucose), isotopically labeled amino acids, palmitate derivatives, and other custom-labeled compounds used in metabolic tracing, nuclear magnetic resonance experiments, and protein turnover studies. Representative awards include a $24,975 order from NHLBI for deuterium oxide to produce deuterated proteins for NMR experiments (September 2, 2025), a $16,200 task order from NIA for deuterated glucose at 99% purity to support mitochondrial protein turnover research (May 7, 2024), and a $88,825 purchase order from NIA for 95 units of 70% deuterium oxide distributed across NIDDK, NIMH, NIDA, and NINDS programs (May 9, 2024). Beyond NIH, Cambridge Isotope Labs supplies newborn screening kits and metabolite standard mixes to the Centers for Disease Control and Prevention — a $221,095 order from CDC for five First Tier Newborn Screening Internal Standard Kits in September 2025, and a $58,585 purchase order from CDC Pittsburgh for 2nd Tier Newborn Screening Kits and Metabolite Standard Mixes in August 2024. The Environmental Protection Agency's Office of Research and Development has placed orders for analytical standards and labeled standards, including a $30,170 purchase order in January 2024 for isotopically labeled analytical pesticide standards. The Office of Naval Research purchased $43,963 in methane-12C at 99.99 atom percent purity (December 2024). Combined, these awards span 44 distinct federal agencies.

Customer concentration is dominated by health research missions. The Department of Health and Human Services' Centers for Disease Control and Prevention Office of Acquisition Services leads by volume and dollars (55 awards, $3.8 million combined potential value), followed distantly by CDC Pittsburgh (22 awards, $1.1 million), NIDDK (29 awards, $601 thousand), and NIH's National Institute on Drug Abuse (11 awards, $481 thousand). These four entities account for 29% of combined potential value across the entire 351-award portfolio. Activity has grown modestly — five awards in 2022 to thirteen in 2024 — with only one award issued in 2026 to date. The recompete cliff is shallow: just one award ($50 thousand) reaches ultimate completion inside the next twenty-four months, indicating minimal near-term recompete exposure.

The two subcontract awards in the source (less than 1% of the portfolio) route through Valkyrie Enterprises, LLC as prime: a July 2025 sub task order for DOD line funding gases and a December 2024 sub task order for gases supporting MIT Lincoln Laboratory research and development activities. Across the prime footprint, Cambridge Isotope Labs' capability portfolio centers on chemical synthesis, isotopic enrichment, and custom labeling — work categorized under PSC Chemicals (129 awards), Laboratory Equipment and Supplies (77 awards), Medical and Surgical Instruments and Supplies (34 awards), and Drugs and Biologicals (32 awards). The vendor's competitive position sits entirely on quality reputation and incumbent supplier status; all awards are firm fixed-price, full-and-open procurements with no competitive set-aside use, meaning Cambridge Isotope Labs holds its federal footprint through scientific necessity and product standardization rather than through privileged access vehicles or SBA certifications.